[Comparative study of retard and non-retard forms of isosorbide-5-mononitrate in coronary patients with stable angina pectoris]. / Sravnitel'noe izuchenie retardnoi i neretardnoi form izosorbid-5-mononitrata u bol'nykh ishemicheskoi bolezn'iu serdtsa so stabil'noi stenokardiei.

An open cross-over trial compared retard and non-retard forms of isosorbide-5-mononitrate (monomac 50D and isomonat, respectively) in 15 patients with stable angina of effort (functional class II-III). Both drugs were found rather effective, they significantly increase exercise tolerance. A single daily dose of monomac 50D reduced the number of anginal attacks. It was well tolerated, caused no serious side effects and had advantages over isomonat taken 2 or 3 times a day.